Neurogene Inc. short interest in 2024
In 2024, Neurogene Inc.'s disclosed short interest ran from 0.20% of shares outstanding on 12 Jan 2024 to 12.24% on 31 Dec 2024, a change of +12.04 percentage points. The year's high was 14.60% on 30 Sep 2024 and its low 0.20% on 12 Jan 2024, averaging 8.80% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 28.85 days on 30 Aug 2024. Full history: Neurogene Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2024 in figures
- Start of year
- 0.20% (12 Jan 2024)
- End of year
- 12.24% (31 Dec 2024)
- Change
- +12.04 pp
- High
- 14.60% (30 Sep 2024)
- Low
- 0.20% (12 Jan 2024)
- Average
- 8.80%
- Highest days to cover
- 28.85 (30 Aug 2024)
- SEC filings marked
- 8
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2024 | 0.20% | 1.00 | |
| 31 Jan 2024 | 0.42% | 1.00 | |
| 15 Mar 2024 | 3.06% | 2.19 | |
| 28 Mar 2024 | 7.05% | 3.79 | 10-K filed, results (8-K) |
| 15 Apr 2024 | 7.69% | 5.99 | |
| 30 Apr 2024 | 7.91% | 11.33 | |
| 15 May 2024 | 7.76% | 17.97 | 10-Q filed, results (8-K) |
| 31 May 2024 | 7.60% | 13.13 | |
| 14 Jun 2024 | 8.25% | 15.20 | |
| 28 Jun 2024 | 8.32% | 3.66 | |
| 15 Jul 2024 | 11.19% | 11.38 | |
| 31 Jul 2024 | 12.11% | 12.75 | |
| 15 Aug 2024 | 13.41% | 15.46 | 10-Q filed, results (8-K) |
| 30 Aug 2024 | 14.02% | 28.85 | |
| 13 Sep 2024 | 13.80% | 20.96 | |
| 30 Sep 2024 | 14.60% | 14.89 | |
| 15 Oct 2024 | 7.19% | 6.07 | |
| 31 Oct 2024 | 7.04% | 9.42 | |
| 15 Nov 2024 | 11.04% | 2.97 | |
| 29 Nov 2024 | 7.91% | 1.19 | 10-Q filed, results (8-K) |
| 13 Dec 2024 | 10.78% | 4.69 | |
| 31 Dec 2024 | 12.24% | 7.00 |
See also: Neurogene Inc.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.